Abstract: Chronic kidney disease (CKD) is known to involve inflammation, oxidative stress and apoptosis. Here, we investigated the impact of curcumin (diferuloyl methane, a phenolic turmeric pigment), which has strong antioxidant, anti-inflammatory and anti-apoptotic activities on kidney structure and function in rats with adenine-induced CKD. Rats were treated for 5 weeks with adenine to induce CKD-like renal damage and combined with three doses of curcumin. Markers of kidney function and oxidative stress were quantified in plasma, urine, renal homogenates and on kidney tissue. Curcumin was found to significantly abate adenine-induced toxic effects such as reduced creatinine clearance, elevated neutrophil gelatinase-associated lipocalin levels and raised urinary N-acetyl-b-D-glucosaminidase activities. Curcumin markedly reduced renal morphological damage and histopathological markers of inflammation, fibrosis and apoptosis. Curcumin further reduced adenine-induced hypertension, urinary albumin, the inflammatory cytokines IL-1b, IL-6 and TNF-a, cystatin C and adiponectin. It restored plasma sclerostin concentrations and lowered oxidative stress in renal homogenates. In animals treated with the two higher curcumin concentrations, alone or in combination with adenine, an increased expression of the antioxidative transcription factor Nrf2 was found as well as up-regulation of the activity of its direct target glutathione reductase, and of an indirect target, the glutathione level. In conclusion, curcumin exhibits salutary effects against adenine-induced CKD in rats by reducing inflammation and oxidative stress via up-regulation of the transcription factor Nrf2.
Chronic kidney disease (CKD) is a major and growing public health problem in both developed [1] and developing countries [2] . CKD is considered a key determinant of the poor health outcome of major non-communicable diseases [3] because of the high prevalence of morbidity and mortality associated with it, mainly due to cardiovascular dysfunction. Till now, there is no drug to improve kidney function in patients with CKD. The current therapeutic approaches to slow down its progression are limited to normalization of insulin, glucose and blood pressure [4] . Therefore, the development of novel therapies to either slow or reverse the deterioration in kidney function is highly needed. In particular, interesting for this are natural products with proven safety profiles.
The pathophysiological basis of CKD and its complications include inflammation, oxidative stress and apoptosis [5] . These features consistently occur in human beings and animals. They are also major mediators of the disease, exerting similar effects in chronic renal failure models in rats [6, 7] . Patients and laboratory animals with CKD have high plasma concentrations of inflammatory mediators (such as C-reactive protein, tumour necrosis factor and other cytokines) and several markers of nitrosative and oxidative stress [8, 9] .
Turmeric (Curcuma longa) is a popular Asian spice that has been utilized for centuries in herbal medicines for the treatment of various diseases such as rheumatism, diabetic ulcers, anorexia, cough and sinusitis [10] . Curcumin (diferuloyl methane) is the main curcuminoid present in turmeric, and is responsible for its yellow colour. Curcumin has been shown to possess a wide spectrum of therapeutic actions that include anti-inflammatory, antioxidant, anticarcinogenic, antimutagenic, anticoagulant and anti-infective effects [11, 12] .
As the pathophysiology of experimental and clinical CKD involves oxidative stress and inflammation [5, 13] , we tested this compound, at three graded doses, against a chemically induced CKD in rats, using histopathological methods as well as several conventional and novel physiological, biochemical and molecular markers.
Animals. Nine-to ten-week-old male Sprague Dawley rats weighing 250-300 g were obtained from the Animal House of Sultan Qaboos University, Oman, and housed as described before [14] . The Treatments. In this study, 48 rats were randomly divided into eight equal groups (n = 6) and were treated as follows:
The 1st group continued to receive the same diet until the end of the study (control group) and was given 2% carboxylmethyl cellulose [CMC (control, 2.0 mL/kg)] by gavage for 35 consecutive days. The 2nd group was treated as above but switched to a powder diet containing adenine (0.25% w/w in feed) for 35 days. The 3rd, 4th and 5th groups were given normal food and curcumin (suspended in 2% CMC) daily by gavage at doses of 37.5, 75 and 150 mg/kg, respectively. The 6th, 7th and 8th groups were given adenine in the feed as in the 2nd group, plus curcumin at the above doses, respectively. The dose of adenine was selected from our recent publications [14, 15] , and the doses of curcumin were chosen to bracket doses reported before in related studies [16, 17] .
Blood pressure (BP) measurement. This was conducted using a Blood Pressure Analysis System TM (BP-2000 SERIES II, Visitech Systems, Apex, NC, USA), as previously reported [18] . Systolic BP and diastolic BP as well as pulse rate were measured at the beginning and the end of the treatment periods.
Experimental protocol. The animals were placed in metabolic cages one day before being killed, and the amount of urine voided during 24 hours was collected. After anaesthesia with intraperitoneally injected ketamine (75 mg/kg) and xylazine (5 mg/kg), blood (about 6 mL) was obtained from the anterior vena cava and placed into heparinized tubes and centrifuged at 900 9 g for 10 min. at 4°C to obtain plasma. The plasma samples harvested were kept frozen at À80°C until analysis. The animals were killed by an overdose of the anaesthetic, and the kidneys were removed, blotted on filter paper, weighed, and part of the right kidney was placed in formalin pending histological analysis. The remainder of the right and left kidneys were individually wrapped in aluminium foil and then dipped in liquid nitrogen and stored at À80°C, pending analysis within 10 days or less.
Biochemical analysis. Plasma samples were assayed for creatinine, urea, uric acid, inorganic phosphate, CK and LDH with an autoanalyser (Mindray BS-120 Chemistry Analyzer, China). The same device was used to quantify creatinine and albumin in urine. Plasma concentration of indoxyl sulphate (IS) was assayed using an HPLC method as previously described [19] . Neutrophil gelatinaseassociated lipocalin (NGAL) was measured using ELISA kits from BioPorto Diagnostics (Gentofte, Denmark), and N-acetyl-b-Dglucosaminidase (NAG) with a colorimetric kit from Diazyme (Poway, USA). Tumour necrosis factor alpha (TNF-a), adiponectin, cystatin C, interleukin-1b (IL-1b), interleukin-6 (IL-6) and sclerostin were measured using ELISA kits from R & D Systems (Minneapolis, MN, USA). Renal reduced glutathione (GSH) concentration was measured using a kit from Cayman (Ann Arbor, USA), and superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR) activities and total antioxidant capacity (TAC) were measured using kits from Abcam (Cambridge, UK 
Results

Physiological data.
Adenine treatment significantly increased the relative kidney weight (table 1) , water intake and urine output and reduced body-weight gain (Table S1 ). The systolic and diastolic blood pressure of the rats treated with adenine and of those treated with adenine and the lowest dose of curcumin (37.5 mg/kg) showed a tendency to be increased 24 hr before the end of the experiments, which was not seen in the other groups (table 1) .
Biochemical measurements.
Loss of kidney function in the adenine-treated rats was characterized by a significantly decreased creatinine clearance, increased urinary concentrations of albumin (table 1) and increased plasma concentrations of creatinine and urea (Table S1 ). Further, in plasma cystatin C, also an indicator of decreasing kidney function, as well as the kidney injury parameter NGAL and the biomarker of proximal tubular damage in urine, NAG, were significantly elevated in adenine-treated rats compared to the healthy control animals (table 1). All these markers of kidney damage were significantly mitigated in a mostly dose-dependent fashion by curcumin. The adenine-treated animals showed signs of uraemia, characterized by an increase of the uraemic toxins indoxyl sulphate, uric acid and inorganic phosphate, as well as of adiponectin (table 1, Table S1 and fig. 1 ). Additionally, chloride concentration and osmolality of urine of adenine-treated animals were significantly reduced, while in plasma chloride and the cell damage marker lactate dehydrogenase was increased (Table S1 ). While it had no influence on the indoxyl sulphate amount and the chloride balance, curcumin was able to ameliorate the other parameters, at least in some of the used concentrations.
Adenine treatment significantly raised the concentrations of the inflammatory cytokines IL-1b, IL-6 and TNF-a ( fig. 1 ).
All changes were reduced significantly by curcumin, but without reaching control levels. The concentration of sclerostin, a glycoprotein and an endocrine regulator in CKD, was significantly depressed by adenine treatment ( fig. 1 ). Treatment with curcumin alone did not affect sclerostin concentration. However, its concentration in the three groups treated concomitantly with adenine and curcumin was significantly higher than in the group treated with adenine alone.
Antioxidant indices.
When compared with the control and with curcumin-onlytreated groups, adenine treatment significantly reduced the concentrations of the antioxidative enzymes catalase, superoxide dismutase as well as the total antioxidant capacity ( fig. 2) . The groups treated with adenine plus curcumin had dose-dependent increases in the antioxidant indices studied, but their level was still significantly below that of the controls and the groups treated with curcumin alone. Adeninetreated rats did not show a significant difference in the expression of the regulator of the antioxidative defence, the transcription factor Nrf2, in their kidneys, when compared to Values are shown as mean AE S.E.M. (n = 6). CKD was induced by the inclusion of A in the feed at a concentration of 0.25% w/w for 35 days, and C or L was given concurrently by oral gavage. On the 35th day of treatment, the rats were placed in metabolic cages to collect urine. At the end of the experiment, blood samples were taken. Differences between the groups were assessed by analysis of variance, followed by multiple comparison tests. *p < 0.05, **p < 0.001, ***p < 0.0001 versus the control group. control rats ( fig. 2 and Figure S1 ). Curcumin as a natural Nrf2 activator increased the abundance of Nrf2 in the kidney, starting at the dose of 75 mg/kg, but reached statistical significance only at 150 mg/kg. In combination with adenine, all three doses of curcumin increased the amount of Nrf2-positive kidney cells significantly compared with the control and the adenine group. One molecular target of Nrf2 is glutathione reductase, an enzyme recycling the antioxidant glutathione, whose activity was significantly suppressed in adenine-treated animals, but was increased by curcumin alone and also in the combination with adenine. Nrf2 also regulates the biosynthesis of glutathione itself. Reduced glutathione was indeed higher in animals treated with curcumin alone and in combination with adenine. 
. Plasma concentrations of IL-1b (A), IL-6 (B), TNF-a (C), cystatin C (D), adiponectin (E) and sclerostin (F) in control rats
, and rats treated with adenine, or adenine plus curcumin. Adenine was added to the feed at a concentration of 0.25%, w/w, for 4 weeks, and curcumin was concomitantly given by gavage (37.5, 75 or 150 mg/kg/day). Each column and vertical bar depict the mean AE S.E.M. (n = 6). Differences between the groups were assessed by analysis of variance, followed by multiple comparison tests. *p < 0.05, **p < 0.001, ***p < 0.0001 versus the control group. Histopathological results. The kidneys of the control rats and the curcumin-only-treated rats had normal kidney architecture and histology using H&E staining ( fig. 3) showing no necrosis (table 1) . Using the Masson trichrome stain, there was also no evidence of fibrosis in these groups (table 1 and fig. 3 ). Further, no apoptotic cells could be detected in the examined sections (table 1 and fig. 3 ). Renal sections from the adenine-treated group showed diffuse acute tubular necrosis (ATN) in more than half of the examined tissue area (table 1 , glutathione reductase (GR) activity (E) and reduced glutathione (GSH, F) in kidneys from control rats, and rats treated with adenine, or adenine plus curcumin. Adenine was added to the feed at a concentration of 0.25%, w/w, for 4 weeks, and curcumin was concomitantly given by gavage (37.5, 75 or 150 mg/kg/day). Each column and vertical bar depicts the mean AE S.E.M. (n = 6). Differences between the groups were assessed by analysis of variance, followed by multiple comparison tests. *p < 0.05, **p < 0.001, ***p < 0.0001 versus the control group. # p < 0.05, tubules, mixed inflammatory cells infiltration of the interstitium and focal tubular atrophy ( fig. 3 ). There were many apoptotic cells and significant interstitial fibrosis (table 1) . Treatment with adenine plus curcumin caused a significant improvement in the histological appearance when compared with the adenine-treated group. Focal areas of ATN were found to involve <25% of the examined areas (table 1) , and there was less dilatation of tubules, less interstitial inflammatory cells infiltration and less tubular atrophy ( fig. 3 ). Masson trichrome showed less interstitial fibrosis in the three dose groups, with a rise in the animals treated with adenine plus 150 mg/kg curcumin (table 1) . As shown in table 1 and fig. 3 , there were also less apoptotic cells.
Discussion
The use of natural products (such as curcumin tested here) in nephroprotection may offer a safe, efficacious and cost-effective alternative to protect kidneys against harmful factors [12] . Further, they might avert the progression of renal impairment to the stage of CKD, end-stage renal disease (ESRD) or cardiovascular disease, where either dialysis or transplantation is the only means of therapy. Both options may be prohibitively expensive or even unavailable in many developing countries [22, 23] . We could show for the first time in a chemically induced model of CKD, the adenine-induced CKD that co-administration of curcumin ameliorated most of the adverse effects inflicted in this model. The mechanism by which adenine induces CKD is not well elucidated. Adenine and its metabolite, 2,8-dihydroxyadenine, have a low solubility and precipitate in the renal tubules leading to their occlusion [24] , resulting in inflammation accompanied by oxidative stress and subsequently renal dysfunction [25] . The adenine model is more reproducible, simpler to conduct and more similar to human CKD than the 5/6 nephrectomy [26, 27] . The beneficial action of curcumin occurred in a dose-dependent manner and encompassed markers of acute as well as of chronic renal damage. Markers usually used for the detection of acute damage and which were detected here in the adenine model and ameliorated by curcumin are NGAL, b-NAG and cystatin C [28] . Further, the tubular necrosis and the occurrence of apoptosis also can be included to the group of markers for early events in kidney damage, here also ameliorated by curcumin, while the interstitial fibrosis and the sclerotic glomeruli seen in the histopathological staining as well as albuminuria and uraemic toxins belong to the chronic markers [29] . Also, the latter were significantly improved by curcumin.
We have previously shown that induction of CKD with adenine in rats results in a significant increase in blood pressure [18] and in histological and morphometric cardiac damage [8] .
In the present work, we have shown that curcumin was effective in dose-dependently ameliorating the rise in blood pressure in rats with adenine-induced CKD. Curcumin has recently been shown to protect the heart in rats with established CKD induced after 5/6 nephrectomy [30] . This is significant because patients with CKD die primarily because of cardiovascular complications, rather than from ESRD [31] .
Therefore, besides the established markers of renal damage, two rather novel markers were tested in this study, adiponectin and sclerostin. The use of novel urinary and plasma biomarkers has been recently highlighted as being able to detect subtle and early renal changes in both chronic and acute renal injury [32] , as well as signs of cardiovascular complications. Adiponectin, secreted from adipose tissue in the healthy organism has anti-inflammatory and anti-atherosclerotic effects. In CKD however, paradoxically, adiponectin is often increased, is associated with arterial stiffness and a predictor of mortality [33] . It is being used now also as a marker for the progression of CKD [34] . In our study, adiponectin was increased in the adenine-treated animals and reduced in animals co-treated with curcumin, but still higher than in the control group. In diabetic rats treated with curcumin, adiponectin was lower than in the control animals, but possibly these two models are not suited to be compared [35] . Sclerostin is an inhibitor of bone formation and seems to play a role in chronic kidney disease-associated mineral and bone disorder [36] . Further, sclerostin seems to be associated with high arterial stiffness in patients with CKD starting from stage 2 on [37] , and can therefore possibly be used as a predictive marker of cardiovascular complications in CKD. While in patients with CKD, sclerostin increases with declining kidney function, contrary to our expectations, sclerostin in adenine-treated rats decreased significantly [38] , which nevertheless is in accordance with results from the 5/6 nephrectomized rat [36] . An explanation could be that sclerostin expression seems to depend on phosphate intake and only high phosphate intake increases the expression in rat [36] .
Most of the indices of oxidative stress and inflammation measured in plasma and kidney homogenates were improved in rats given curcumin, supporting our hypothesis that the basis of the palliative action of curcumin on adenine-induced CKD is most likely the antioxidant and anti-inflammatory actions of curcumin. One of these actions is the activation of the transcription factor Nrf2, which through a feedback mechanism, includes regulation of its own expression levels. Nrf2 is involved in the regulation of the expression of several cytoprotective genes encoding antioxidant proteins which can antagonize oxidative and inflammatory damage [39] . In the recent work, Nrf2 staining of renal tissues has shown a slight non-significant decrease of Nrf2 levels in the adenine-treated animals, while the Nrf2 targets SOD, catalase and GSH reductase were reduced significantly. The lack of significance can be explained by the chosen readout, the expression levels of Nrf2, which seem not to react as sensitive as did the expression levels of the studied Nrf2 targets. Other studies found significant reduction of Nrf2 activity by adenine treatment [40, 41] . A decrease of Nrf2 activity was also reported from other animal models of chronic and acute kidney disease [42, 43] . In contrast to these studies, but in accordance with in vitro studies and our own study with another Nrf2 activator in hypertensive animals, curcumin alone starting from 75 mg/ kg did significantly increase Nrf2 expression in the kidney [44, 45] . This also had an impact of the Nrf2 targets glutathione reductase and reduced glutathione in the kidney.
In summary, curcumin in our study lowered adenine-induced parameters of renal damage by fortifying the cellular oxidative defence and thereby reducing the inflammation. This adds important evidence of the nephroprotective potential of curcumin, suggesting that curcumin may potentially be a promising candidate as an agent to prevent or palliate CKD in human beings. This highly pleiotropic curcuminoid molecule is one of the most important and well-studied natural products [46] . In our work, no overt ill effects were noted in the rats treated with the three doses of curcumin. The safety of this compound has been shown before in laboratory animals and in human beings [10] , and more recently, short-term intravenous dosing of a liposomal formulation of it has been shown to be safe up to a dose of 120 mg/m 2 in human beings [47] .
Conclusion
This work shows that curcumin given concomitantly in adenine-induced CKD significantly abated most of the physiological, biochemical, histopathological and molecular actions of adenine in rats by fortifying the antioxidative defence in the kidney. Further studies to confirm the safety and therapeutic usefulness of curcumin in CKD are warranted.
